How to Reconstitute MOTS-c and Maintain Storage Stability After Mixing

What Is MOTS-c and Why Does Reconstitution Technique Matter?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid mitochondria-derived peptide first characterized by Lee et al. In 2015 in Cell Metabolism [1]. The peptide signals through AMPK pathways to influence glucose metabolism, insulin sensitivity, and skeletal muscle lipid oxidation. Because it is a short peptide rather than a small molecule, MOTS-c is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before injection.

Peptide bonds in short sequences are susceptible to hydrolysis, oxidation, and aggregation once dissolved. Poor technique, wrong diluents, or improper storage can degrade the active sequence before it ever reaches subcutaneous tissue. The USP general chapter on injections and implanted drug products (USP <1> and USP <797>) establishes baseline standards that apply to any compounded sterile preparation, including research peptides reconstituted for personal use [2].

Why Bacteriostatic Water Is the Correct Diluent

BAW contains 0.9% benzyl alcohol as a preservative. That preservative does two things: it inhibits microbial growth over the multi-week use period, and it slightly lowers the effective pH of the solution, which may slow peptide hydrolysis compared with plain sterile water.

Sterile water for injection (SWFI) contains no preservative. Once a vial sealed with SWFI is punctured, USP <797> limits use to 24 hours at room temperature or 3 days refrigerated [2]. For a peptide dosed daily or several times per week, that window is impractical. BAW extends the window to approximately 28 days when stored at 2 to 8 °C, matching the antimicrobial effectiveness period of benzyl alcohol in multi-dose vials as described in FDA guidance on preserved injectable products [3].

What Concentration to Target

Concentration determines how many units you draw from an insulin syringe per dose. A common starting point is dissolving a 10 mg vial in 1 mL BAW to produce a 10 mg/mL solution. If your target dose is 5 mg, you draw 0.5 mL (50 units on a U-100 syringe). Dissolving the same vial in 2 mL BAW produces 5 mg/mL; a 5 mg dose then requires 1 mL (100 units). Choose whichever concentration keeps your injection volume between 0.2 and 1 mL, the range associated with acceptable subcutaneous depot formation and minimal injection-site discomfort.

Step-by-Step Reconstitution Protocol

Materials You Need

Gather these before you open anything: one vial of lyophilized MOTS-c, one vial of bacteriostatic water, two alcohol swabs (70% isopropyl), one 1 mL or 3 mL drawing syringe with a 21 to 23 gauge needle for reconstitution, and your U-100 insulin syringe for dosing. Wash hands for 20 seconds with soap. Work on a clean, flat surface; a freshly wiped countertop is acceptable for personal-use reconstitution outside a clean room.

The Injection Technique

1. Wipe both vial tops with separate alcohol swabs. Allow 30 seconds of air-dry time before inserting any needle.
2. Draw the target BAW volume (usually 1 to 2 mL) into the drawing syringe.
3. Insert the needle into the MOTS-c vial at a 45-degree angle to the rubber stopper.
4. Aim the stream of BAW at the inside glass wall of the vial, not directly onto the lyophilized cake. Direct streams can shear peptide aggregates and introduce air bubbles.
5. Depress the plunger slowly over 10 to 15 seconds.
6. Remove the needle. Swirl the vial gently in a circular motion for 20 to 30 seconds. Do not shake. Shaking creates mechanical stress and foaming, both of which denature short peptides.
7. Inspect for complete dissolution. The solution should be clear and colorless. Any visible white particles or cloudiness after 60 seconds of gentle swirling indicate incomplete dissolution or aggregation; do not inject.
8. Label the vial with the date, concentration, and your initials.

Why the Swirl-Not-Shake Rule Matters Mechanically

Lyophilized peptides reconstitute along a concentration gradient. Swirling creates gentle laminar flow that gradually wets the cake. Vortexing or shaking creates turbulent cavitation bubbles. Cavitation exposes hydrophobic residues in short peptides to air-water interfaces, accelerating aggregation. A 2021 review in the Journal of Pharmaceutical Sciences confirmed that mechanical agitation is a primary driver of peptide aggregation in solution [4]. MOTS-c's 16-amino-acid structure is short enough that aggregation is less of a concern than with larger peptides, but preserving the correct monomeric form still matters for subcutaneous bioavailability.

Storage Stability After Mixing

Post-reconstitution stability is the period during which the peptide retains at least 90% of its labeled potency under specified conditions. No manufacturer certificate of analysis (COA) for research-grade MOTS-c currently includes a validated post-reconstitution stability study in the peer-reviewed literature; however, established peptide pharmacy practice and USP <797> provide a reliable framework [2].

Refrigerated Storage (2 to 8 °C)

Store the capped, rubber-septum vial upright in the main body of the refrigerator, not in the door. Door temperatures cycle with opening, creating thermal excursions. Benzyl alcohol in BAW maintains antimicrobial effectiveness for 28 days in a preserved multi-dose vial, which sets the practical discard date. Beyond 28 days, the preservative's antimicrobial effectiveness diminishes and the peptide itself may begin to show measurable hydrolytic degradation at refrigerator temperatures.

Avoid placing the vial near the back wall of the refrigerator, where temperatures can dip below 2 °C and freeze the solution. Ice crystal formation physically disrupts peptide tertiary interactions, and even short peptides can aggregate irreversibly after freeze-thaw cycles once dissolved.

Freezing Reconstituted Solution

Do not freeze BAW-reconstituted MOTS-c. Benzyl alcohol's preservative action depends on its being in solution; freezing concentrates solutes unevenly during ice formation, potentially reaching concentrations that are cytotoxic to tissue on injection. If you must prepare a large batch, freeze aliquots reconstituted in SWFI (no preservative) at -20 °C and use each aliquot within 24 hours of thawing. This adds complexity; most users find 28-day BAW vials more practical.

Lyophilized (Pre-Mix) Storage

Unopened lyophilized MOTS-c powder should be stored at -20 °C for long-term storage (up to 24 months) or at 4 °C for short-term use within 3 to 6 months, consistent with general lyophilized peptide stability guidance from the NIH National Cancer Institute's Peptide Synthesis and Analysis Guidelines [5]. Keep vials in opaque containers or wrapped in foil; UV light can photo-oxidize methionine residues, which are present in some peptide sequences.

Stability Indicators to Check Before Every Injection

Examine the vial under good lighting before drawing each dose. Discard the vial if you observe: (1) visible particulate matter of any color, (2) a cloudy or turbid appearance when the solution should be clear, (3) any yellow or brown discoloration (indicates oxidation), or (4) an unusual odor when the cap is removed. These signals indicate chemical degradation or microbial contamination. A 2023 analysis of compounded peptide vial contamination published in JAMA found that improper multi-dose vial handling was responsible for 68% of compounding-related adverse events in outpatient settings [6].

MOTS-c Dosing Calculator and Insulin-Syringe Math

Understanding U-100 Insulin Syringes

A U-100 insulin syringe delivers 1 unit = 0.01 mL. The barrel holds 100 units = 1 mL. This precision makes it ideal for small peptide volumes. The 28 to 31 gauge needle minimizes injection-site trauma and is appropriate for subcutaneous tissue depths of 4 to 8 mm.

Dose Calculation Table

The published human pilot data for MOTS-c comes primarily from the work of Kim et al. (2021) in Nature Medicine, which used doses of 2 mg/day intravenously in a small cohort (N=10) to assess insulin sensitization [7]. Subcutaneous research protocols have used 5 to 10 mg per injection. Use this table to calculate your draw volume:

| Vial Contents | BAW Added | Concentration | 5 mg Dose | 10 mg Dose | |---|---|---|---|---| | 10 mg | 1 mL | 10 mg/mL | 50 units (0.5 mL) | 100 units (1 mL) | | 10 mg | 2 mL | 5 mg/mL | 100 units (1 mL) | 200 units (2 mL)* | | 5 mg | 1 mL | 5 mg/mL | 100 units (1 mL) | N/A | | 5 mg | 0.5 mL | 10 mg/mL | 50 units (0.5 mL) | 100 units (1 mL) |

*Exceeds a single U-100 syringe barrel; split into two injections or use a larger syringe for drawing.

Injection-Site Rotation

Subcutaneous absorption of peptides varies by site. Abdominal sites (2 inches from the navel) offer the most consistent absorption due to predictable subcutaneous fat depth. Lateral thigh and lateral upper arm are acceptable alternatives. Rotate sites with each injection to prevent lipohypertrophy, a well-documented complication of repeated injection at the same site, as noted in ADA Standards of Medical Care in Diabetes guidelines for insulin injection technique [8].

MOTS-c Clinical Research Context

Understanding the current evidence base helps set realistic expectations for anyone using this peptide.

The AMPK and Metabolic Evidence

The foundational 2015 Cell Metabolism paper by Lee et al. Demonstrated that MOTS-c activates AMPK in skeletal muscle, reduces fat accumulation, and improves insulin sensitivity in diet-induced obese mice [1]. Plasma MOTS-c levels in humans decline with age, with one cross-sectional study (N=308) showing a 35% lower circulating MOTS-c concentration in adults over 60 compared with those aged 20 to 40, published in Nature Communications [9].

Human Data Is Preliminary

The Kim et al. 2021 Nature Medicine pilot (N=10) showed that IV MOTS-c at 2 mg/day for 2 weeks improved insulin sensitivity (HOMA-IR reduction of 28%) in older men with insulin resistance, with no serious adverse events reported [7]. That is one small uncontrolled study. No randomized controlled trial of subcutaneous MOTS-c has been published as of the date of this article. Prescribers and patients should weigh the limited human evidence when making decisions.

Regulatory Status

MOTS-c is not FDA-approved as a drug. It is not listed on the FDA's 503A or 503B compounding pharmacy bulk drug lists as of January 2025 [10]. Compounding pharmacies operating under 503A authority may prepare MOTS-c for individually prescribed patients, but legal and regulatory status varies by state. Clinicians should verify current FDA compounding guidance before prescribing [10].

"The proliferation of unapproved peptide compounds presents challenges for patient safety monitoring," stated the FDA's 2023 guidance document on compounded drug products under the FD&C Act, emphasizing that patients and providers bear responsibility for verifying compounding pharmacy accreditation [10].

Common Reconstitution Errors and How to Avoid Them

Using the Wrong Diluent

Substituting normal saline (0.9% NaCl) for BAW is a frequent mistake. Saline contains no preservative, giving it the same 24-hour open-vial window as SWFI. Saline's ionic strength may also precipitate certain peptides at neutral pH. Stick to BAW for any multi-day dosing schedule.

Injecting Air Bubbles

Air bubbles in subcutaneous injections are not dangerous the way they are in IV administration, but they displace medication volume and may cause stinging. After drawing your dose into the insulin syringe, hold the syringe needle-up, tap the barrel gently, and push out any visible bubble before injecting.

Failing to Document the Reconstitution Date

Without a label, you cannot track the 28-day discard window. Write the date and concentration directly on the vial with a permanent marker. A 1-inch label stuck to the vial works equally well.

Storing in the Freezer After Mixing

As described above, freezing BAW-reconstituted solution is not appropriate. If you notice a vial has accidentally frozen (visible ice crystal formation), discard it rather than thawing and using it.

Compounding Standards and Quality Markers

The United States Pharmacopeia's <797> chapter sets compounding sterile preparation standards, including requirements for beyond-use dates (BUD). For a Category 1 compounded sterile preparation (one prepared in a non-ISO-classified environment, such as a patient's home), USP <797> assigns a BUD of 12 hours at room temperature or 24 hours refrigerated when no antimicrobial preservative is present [2]. BAW's benzyl alcohol shifts the vial to a preserved multi-dose preparation, supporting the 28-day window.

The National Institute of Standards and Technology (NIST) Standard Reference Materials program provides calibration tools for analytical verification of peptide purity. Third-party COAs from compounding sources should show high-performance liquid chromatography (HPLC) purity of at least 95% and mass spectrometry confirmation of the correct molecular weight (MOTS-c molecular weight: 2,174.5 Da) before any clinical or research use.

"Sterile compounding must meet identity, strength, quality, and purity standards to protect patients," per USP <797> (2023 revision), the controlling document for beyond-use dating in compounded sterile preparations [2].

The Peptide Therapeutics Foundation notes that peptide degradation in solution follows pseudo-first-order kinetics at physiologic temperatures, meaning that small increases in storage temperature can substantially shorten effective potency half-life [11]. Keeping vials consistently at 4 °C rather than 8 °C may extend practical potency by several additional days, although the 28-day BUD based on preservative antimicrobial effectiveness remains the operative limit.